Public distrusts pharma on cancer drive; Perrigo drops nice surprise on Street; FDA approves Doxil generic

@FiercePharma: U.S. government finally gets payment rule published. News | Follow @FiercePharma

@EricPFierce: AstraZeneca, Bristol-Myers Squibb create 'Diabetes Inc.,' to give complete attention to diabetes treatment sales. More | Follow @EricPFierce

@AlisonBFierce: A study of the first new TB vaccine in 90 years showed it offered no added benefit to the current vaccine. News | Follow @AlisonBFierce

> A Lilly Oncology-sponsored survey found that 60% of respondents think drugmakers would rather make money treating cancer and than find ways to cure it. Story

> The GAVI global vaccines group will pay to help vaccinate about 180,000 girls in Africa and Asia against cervical cancer with vaccines from Merck ($MRK) and GlaxoSmithKline ($GSK). Story

> The FDA has approved Hyperion Therapeutics' ($HPTX) Ravicti (glycerol phenylbutyrate) for the chronic management of some urea cycle disorders (UCDs) in patients ages 2 years and older. Story

> The House Energy and Commerce Committee has given the FDA until Feb. 25 to provide all the documents on New England Compounding Center, which is tied to a nationwide meningitis outbreak, or face a subpoena. Item

> The government in India is creating three more branches of the Delhi State Cancer Institute to serve more patients. Story

> The FDA says it has approved first generic of J&J cancer drug Doxil from Sun Pharma to help end shortage. Release

Medical Device News

 @FierceMedDev: Swiss team: Nanoscale tissue check boosts breast cancer Dx. More | Follow @FierceMedDev

 @MarkHFierce: GE and the N.F.L. will jointly develop new imaging tech to spot concussions. News| Follow @MarkHFierce

 @DamianFierce: Icon is spending $52M on Cross Country Healthcare's clinical trials business. Report | Follow @DamianFierce

> AdvaMed targets Puerto Rico device tax hike as unfair burden. News

> Covidien ticks toward pharma spinoff. Article

> Yogurt, pacemakers compel conflict-of-interest issues in Florida. Item

Biotech News

 @FierceBiotech: Popular this weekend: Merck R&D calls for a time-out on osteo blockbuster hopeful. Story | Follow @FierceBiotech

@JohnCFierce: Interesting to see Medicines Co. pay Alnylam $25M upfront for early-stage PCSK9 program. More | Follow @JohnCFierce

@RyanMFierce: $GILD says SVR 67% in oral combo is same as SVR on interferon group in Ph3 FISSION study in hep C types 2&3, meets primary endpoint. Release | Follow @RyanMFierce

> Bitter setback as TB vaccine fails to protect infants in key study. News

> Rockwell shares surge as PhIII iron deficiency study offers upbeat outcomes. Report

> Alnylam licenses away hot PCSK9 prospect in 'small' $205M deal. Story

CRO News

> Parexel brightens 2013 outlook after strong quarter. Story

> BioClinica eyed for $123M buyout, eventual merger. News

> Indian clinical trials: Private group steps in to increase transparency. More

> Patheon brings bioavailability service to EU with plant expansion. Report

Biotech IT News

> Cypher Genomics chief speaks out from DNA data-crunching crowd. Story

> Clinical trials software player agrees to $123M buyout. News

> Boehringer unleashes iPhone app amid COPD blitz. Report

> Biopharma targets bioinformatics aces in R&D overhaul. Article

And Finally...The rapidly-growing Perrigo ($PRGO) announced earnings today which were enhanced by recent acquisitions and exceeded expectations on the Street. Story
 

Suggested Articles

The efficacy between Keytruda and FerGene's nadofaragene firadenovec look comparable in their studies, though Merck has at least one upper hand.

Thursday, the FDA approved the first three generic versions of Gilenya, but they may not hit the market anytime soon due to ongoing litigation.

Gilead is hoping to score a patent extension on TAF meds, but patient advocates say that would reward conduct that harmed patients.